Jci_page_head_homepage_01 Jci_page_head_homepage_02
Annick Raas-Rothschild, Valerie Cormier-Daire, Ming Bao, Emmanuelle Genin, Remi Salomon, Kevin Brewer, Marsha Zeigler, Hanna Mandel, Steve Toth, Bruce Roe, Arnold Munnich, William M. Canfield
Published in Volume 105, Issue 5
J Clin Invest. 2000; 105(5):673–681 doi:10.1172/JCI5826
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 7

Enzymatic characterization of the mutant GlcNAc-phosphotransferase. Normal human skin fibroblasts (Wt); and skin fibroblasts from patients with classical MLIII (GM2425) and variant MLIII (GM3391); and patient VI:8 (pedigree 1), patient II:3 (pedigree 3), were cultured and a solubilized membrane fraction prepared as described in Methods. GlcNAc-phosphotransferase was assayed using both the lysosomal enzyme uteroferrin and α-methylmannoside as acceptors and calculated as pMol GlcNAc-1-phosphate transferred per milligram of cell protein per hour. The data are expressed as a percentage of the activity observed in the wild-type cell line.